聚甲基丙烯酸甲酯(PMMA)骨水泥是广泛应用于骨科、神经外科等领域的生物填充材料，但其存在细胞毒性、致敏性及固化收缩等缺陷严重影响疗效，亟需改进。申请人前期研制出国际上首个“吸水自膨胀”骨水泥类材料(PMMA-PAA-PSt)，从根本解决上述问题。但该材料的力学强度和均一性不足制约其进一步临床应用。近期，项目组经筛选发现加入氧化石墨烯(GO)和甲基丙烯酸羟乙酯(HEMA)能分别从固液两相优化材料结构和性能。因此，本研究将在此基础上进一步优化合成工艺，提高材料的强度和膨胀后均一性，同时利用细胞生物学研究方法系统评价材料对骨细胞生物学行为的影响，并以此指导材料合成。再利用动物模型检测疗效、分析“膨胀效应”对界面骨组织的生物学影响，得到最优膨胀比率并优化工艺，最终获得一种满足临床需求、生物相容性良好、具有自主知识产权的新型骨水泥材料。本研究具有及其重要的理论和现实意义。

Polymethyl methacrylate (PMMA) cement has been widely used in orthopaedic and neurological surgeries. However, the clinical applications of PMMA cement were limited by several main flaws: cytotoxity, allergic reaction and volume shrinkage. In our previous research, polyacrylic acid (PAA) and polystyrene (PSt) were firstly copolymerized with PMMA and forming a novel trimer: PMMA-PAA-PSt, which is the first injectable self-expandable bone cement in worldwide, and could overcome the imperfection of PMMA. Despite all this, the feature of low mechanical strength and inhomogeneous restrict its further application. Recently, we found adding graphene oxide (GO) in solid phase and hydroxyethyl methacrylate (HEMA) in liquid phase could improve the three-dimensional structure and the mechanical feature of the PMMA-PAA-PSt polymer. In this project, therefore, we will optimize the synthetic process based on this finding to generate homogenous cement with the appropriate mechanical strength for clinical use. Meanwhile, we also will evaluate the biological performance of primary osteocyte co-cultured with the cement component in the medium, by using cellular biological studies, which is also a parameter for evaluation in synthetic procedure. Then, the expansion effect for the osteoblasts growing in the interface between cement and tissue will also be investigated by cell biological experiment in animal model to optimize the cement synthesis. Finally, we will develop novel biocompatibility cement, which is suitable for clinical usage and possess self-owned intellectual property right.